Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Molecular Diagnostics » At JPM, Natera CEO Lays Out Growth Potential for NIPT, Transplant, Cancer Testing

At JPM, Natera CEO Lays Out Growth Potential for NIPT, Transplant, Cancer Testing

Jan 13, 2021
|
Julia Karow

NEW YORK – Natera officials said on Tuesday that the company processed more than 1 million tests in 2020, among them about a million for the reproductive health business alone. The company also exceeded its pre-pandemic goals for growing its Prospera transplant testing business while launching its Signatera cancer test and securing reimbursement for it.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Should Also Work

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

Worries About Increased Deadliness

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

Merck Stops SARS-CoV-2 Vaccine Development

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

PLOS Papers on Rare Venous Thromboembolism Variant, Vector Mosquito LncRNAs, More

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.

Feb
11
Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
17
Featured Webinar

Single-Cell Multiomics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19

Sponsored by
BioLegend

Host immune responses play a central role in controlling SARS-CoV-2 infection, but they remain incompletely characterized and understood.

Feb
18
Featured Webinar

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

What's Popular?

In Molecular Diagnostics

  1. Infectious Disease Test Firm Talis Biomedical Files for IPO

  2. NeoGenomics to Boost Growth of Pharma, Informatics Divisions Through CDx Agreements, Acquisitions

    Premium

  3. Caris Shares Data for AI-Driven Tumor Origin Prediction, Hinting at Diagnostic, Patient Benefit

    Premium

  4. Lucira Health Files for $115M IPO

  5. Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.